Resources
The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
Filter by:
Topic
Topic
- Accountable Care Organizations
- Alternative Payment Models
- (-) Biopharmaceutical Innovation
- Bundled Payments
- Clinical Pathways
- Decision Frameworks
- Elements of Value
- Evidence for Decision Making
- (-) Formulary/Benefit Design
- Formulary Development
- Good Practices for Evidence
- Health Care Quality Measures
- Health Spending
- Health Spend Management
- High-Deductible Health Plans
- Impact on Outcome & Spending
- Individual Treatment Effects & Personalized Access
- IRA Implementation
- Low-Value Care
- Pandemic Response
- Patient Cost Sharing
- (-) Paying for Cures
- Policy & Regulatory Barriers
- Real-World Data
- (-) Real-World Evidence
- Regulatory Barriers & Challenges
- (-) Understanding Health Spending
- Utilization Management & Step Therapy
- Value-Based Contracts
- Value-Based Insurance Design
- Value Assessment
- Value Assessment Frameworks
- Value Assessment Methods
Resource Type
Display Only
Showing 187 Results
Principles for Sound Pharmacy and Therapeutics Practices: What’s Next
AMCP's Partnership Forum, “Principles for Sound Pharmacy and Therapeutics (P&T) Practices: What’s Next?” focused on the current state of P&T committees, challenges faced by these committees…
Updated Tools Developed to Communicate High-Quality Information About New Treatments and Inform Health Plan Coverage and Reimbursement
NPC said that with the release of the new AMCP Format for Formulary Submissions, biopharmaceutical manufacturers and health plans will have a practical guide to exchange clinical and economic…
NPC Submits Comments on Cures 2.0
The National Pharmaceutical Council (NPC) submitted comments in response to a public request for input on Cures 2.0, an “effort to modernize coverage and access to life-saving cures in the United…
What's It Like to Be an NPC Fellow?
Our current and previous fellows share some inside tips
Little Consistency in Evidence Cited by Commercial Health Plans for Specialty Drug Coverage
Evidence cited by payers in coverage decisions for specialty medicines varies significantly, with health plans only citing the same study in 15% of health plan coverage policies for a given drug and…
New Study Reveals Little Consistency in Evidence Cited by Commercial Health Plans for Specialty Drug Coverage
When the health care community talks about evidence-based medicine, it’s usually in the context of efforts to ensure clinicians are delivering treatments to patients that align with the best…
Second National Pharmaceutical Council and Health Affairs Forum to Explore Emerging Health Spending Solutions
NPC, Health Affairs and several Going Below The Surface Forum partners on Sept. 11 are hosting a discussion among health policy experts on emerging solutions to rising U.S. health spending
NPC in Specialty Pharmacy Times: Why We Need to Consider the Proven Value of Drug Therapies
In his latest column for Specialty Pharmacy Times, National Pharmaceutical Council (NPC) President and Chief Executive Officer Dan Leonard explores recent research from the NPC and RTI Health…
Six Ways to Make Real-world Evidence Methods More Transparent
Acceptance of studies based on “real-world data” remains limited, partly because the research methods used to generate usable evidence are not always transparent. That perception could change thanks…
NPC in Chain Drug Review: The Long-term Health Benefits of Biopharmaceuticals
In his latest column for Chain Drug Review, National Pharmaceutical Council (NPC) President and Chief Executive Officer Dan Leonard highlights the importance of taking a holistic view of health care…
Tackling Low-Value Care Will Take a Group Effort
During a briefing with partners of the Going Below The Surface Forum, three leaders in the effort to reduce low-value care in the United States explained why this has been such a tough challenge to…
NPC in Specialty Pharmacy Times: International Drug Pricing Index Model Could Restrict Innovation, Access
NPC President and CEO Dan Leonard says that CMS's proposal to tie American drug prices to an international pricing index undermines efforts to prioritize value and improve patient outcomes over…
How Can We Elevate the Patient Voice in Value-Based Payment for Oncology?
A new study from the National Pharmaceutical Council (NPC) and Discern Health sheds new light on progress in making value-based reimbursement mechanisms, like accountable care, patient-centered.
Paying for Cures: Ensuring Patient Access and System Sustainability
One of the most vexing challenges facing the U.S. health care system is how payers and biopharmaceutical innovators can work together to ensure that curative treatments are more broadly accessible to…
Patient-Community Perspectives on Real-World Evidence: Enhancing Engagement, Understanding, and Trust
Researchers found that while most patient organizations were initially unaware of real-world evidence (RWE) and its actual or potential uses, they recognized the ability of RWE to provide relevant…
Patients on RWE: WIIFM? (What’s In It for Me?)
In an article published in The Patient, NPC and the National Health Council found that while most patients were initially unaware of real-world evidence (RWE) and its actual or potential uses,…
Reconciling the Seemingly Irreconcilable: How Much Are We Spending on Drugs?
In this study from the National Pharmaceutical Council and IQVIA, researchers developed a model to understand the underlying methodological inputs that drive the substantial variation in drug…